IRADIMED (IRMD) Chief Commercial Officer receives 1,150 RSU equity grant

Rhea-AI Filing Summary

IRADIMED CORP Chief Commercial Officer Jeff Chiprin reported an equity award of 1,150 restricted stock units (RSUs). These RSUs were granted under Iradimed Corporation's 2023 Equity Incentive Plan and carry no cash exercise price.

The RSUs convert into common stock on a one-for-one basis. They vest in three equal annual installments beginning on December 7, 2026, and upon each vesting date Mr. Chiprin will receive the corresponding number of common shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Chiprin Jeff

Role Chief Commercial Officer

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	1,150	$0.00	--

Holdings After Transaction: Restricted Stock Units — 1,150 shares (Direct)

Footnotes (1)

1. Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. The reporting person received RSUs under Iradimed Corporation's 2023 Equity Incentive Plan. The RSUs vest in three equal annual installments beginning on December 7, 2026. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chiprin Jeff

(Last) (First) (Middle)

C/O IRADIMED CORPORATION

12705 INGENUITY DRIVE

(Street)

ORLANDO FL 32826

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IRADIMED CORP [ IRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	03/03/2026		A		1,150		(2)	(2)	Common Stock	1,150	$0	1,150	D

Explanation of Responses:

1. Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.

2. The reporting person received RSUs under Iradimed Corporation's 2023 Equity Incentive Plan. The RSUs vest in three equal annual installments beginning on December 7, 2026. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.

	/s/ Jeff Chiprin	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did IRADIMED CORP (IRMD) report for Jeff Chiprin?

IRADIMED CORP reported that Chief Commercial Officer Jeff Chiprin received 1,150 restricted stock units. The award was made under the company’s 2023 Equity Incentive Plan and represents a non-cash equity grant rather than an open-market stock purchase or sale.

How many restricted stock units did IRMD grant to Chief Commercial Officer Jeff Chiprin?

Jeff Chiprin received an award of 1,150 restricted stock units from IRADIMED CORP. These RSUs convert into common stock on a one-for-one basis, increasing his potential future ownership as they vest over time under the company’s equity incentive plan.

When do the newly granted IRMD restricted stock units to Jeff Chiprin vest?

The RSUs granted to Jeff Chiprin vest in three equal annual installments beginning on December 7, 2026. Each year as a portion vests, he will receive common shares equal to the vested RSUs, aligning compensation with longer-term company performance.

What is the conversion rate of IRMD restricted stock units granted to Jeff Chiprin?

Each restricted stock unit granted to Jeff Chiprin converts into one share of IRADIMED CORP common stock. This one-for-one conversion means the 1,150 RSUs, once fully vested, translate into 1,150 common shares, directly linking the award to share ownership.

Under which plan were the IRMD restricted stock units granted to Jeff Chiprin?

The RSUs were granted under Iradimed Corporation's 2023 Equity Incentive Plan. This plan is used to provide stock-based compensation, and in this case delivers 1,150 RSUs that vest over three years, encouraging long-term alignment between management and shareholders.